Open AccessExpert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary
Author(s) -
Peter Rieckmann,
Diego Centonze,
Gavin Giovani,
Le H. Hua,
Celia OrejaGuevara,
Daniel Selchen,
Per Soelberg Sørensen,
Patrick Vermersch,
Heinz Wiendl,
Hashem Salloukh,
Bassem Yamout
Publication year - 2023
Publication title -
neurodegenerative disease management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.674
H-Index - 23
eISSN - 1758-2032
pISSN - 1758-2024
DOI - 10.2217/nmt-2022-0027
Subject(s) - plain language , covid-19 , expert opinion , cladribine , medicine , family medicine , virology , natural language processing , computer science , linguistics , intensive care medicine , infectious disease (medical specialty) , outbreak , disease , philosophy
People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets.